Olatec gets $40M to put anti-inflammatory in late-stage trial; Enliven goes public, raises $165M
A US and Dutch biotech closed its $40 million Series A to bankroll more studies of its oral …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
